This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Optical Frequency Domain Imaging for Non-melanoma Skin Cancers (OFDI)

This study is currently recruiting participants.
See Contacts and Locations
Verified August 2017 by Benjamin Vakoc, Massachusetts General Hospital
Information provided by (Responsible Party):
Benjamin Vakoc, Massachusetts General Hospital Identifier:
First received: August 8, 2012
Last updated: August 7, 2017
Last verified: August 2017
The purpose of this research study is to find out if a non-invasive imaging device called Optical Frequency Domain Imaging (OFDI) can help doctors to see the tissue and blood vessels that are related to non-melanoma skin cancers. OFDI was designed to see microscopic details of your skin without needing to use any invasive techniques such as surgery or biopsy.

Condition Intervention
Non-Melanoma Skin Cancer (NMSC) Device: OFDI

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Optical Frequency Domain Imaging for Non-melanoma Skin Cancers

Resource links provided by NLM:

Further study details as provided by Benjamin Vakoc, Massachusetts General Hospital:

Primary Outcome Measures:
  • Successful imaging of lesion [ Time Frame: After completion of imaging session ]
    Images acquired of NMSC

Estimated Enrollment: 90
Actual Study Start Date: March 1, 2017
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NMSC Imaging
Optical Frequency Domain Imaging (OFDI) will be used to look at non melanoma skin cancer (NMSC) lesion(s).
Device: OFDI
Imaging of skin
Other Names:
  • Optical Imaging
  • Optical Coherence Tomography
  • OCT
  • Optical Frequency Domain Imaging

Detailed Description:

Non-melanoma skin cancer (NMSC) is the most common cancer in the United States, with more than 750,000 diagnosed patients treated every year. Its prevalence and incidence have significantly increased over the past two decades and it has been estimated that 20% of all Americans will develop this type of cancer during their lifetime (Neville et al., 2007). Biopsy and surgical resection of NMSC can result in tissue mutilation and scaring. Therefore, there is a need for new imaging technologies that can be used to non-invasively guide biopsy and surgery.

Optical Frequency Domain Imaging (OFDI) is a second-generation imaging implementation of optical coherence tomography (OCT) developed at the Wellman Center. OFDI provides high-resolution three-dimensional imaging in tissue. It uses an interferometric depth-sectioning technique and employs a near-infrared light source. Through analysis of phase information in the recorded signal. OFDI can detect blood vessels within tissues and tumors. Importantly, OFDI-based vascular imaging can be performed without the need for exogenous contrast agents, making it relatively easy to deploy in clinical settings.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female subjects with Fitzpatrick skin type I-VI
  2. Subjects with ages between 18 and 80 years of age
  3. Presence of at least one NMSC lesion

Exclusion Criteria:

  1. Subjects with active localized or systemic infections
  2. Subjects participating in potentially confounding clinical studies of investigational therapies, either drug or device.
  3. Subjects taking any topical/systemic chemotherapy or immunosuppressants
  4. Subjects who are pregnant and/or breastfeeding
  5. Subjects with tape adhesive allergies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01662713

Contact: Benjamin Vakoc, PhD 617-726-0695
Contact: Benjamin Vakoc, PhD

United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Benjamin J Vakoc, PhD         
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Benjamin Vakoc, PhD Massachusetts General Hospital
  More Information

Responsible Party: Benjamin Vakoc, Assistant Professor, Massachusetts General Hospital Identifier: NCT01662713     History of Changes
Other Study ID Numbers: 2012P002430
Study First Received: August 8, 2012
Last Updated: August 7, 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Benjamin Vakoc, Massachusetts General Hospital:
skin cancer
optical imaging
optical coherence tomography
optical frequency domain imaging

Additional relevant MeSH terms:
Skin Neoplasms
Neoplasms by Site
Skin Diseases processed this record on September 19, 2017